Background: Protein arginine N-methyltransferase 6 (PRMT6) was deemed to be indispensable in the variety of biological processes. Upregulated PRMT6 was found in various human diseases including cancer. Herein, we investigated the performance of PRMT6 methylation in the diagnosis for CRC.
Methods:
A quantitative methylation-specific polymerase chain reaction (qMSP) method was used to measure PRMT6 promoter methylation. The percentage of methylated reference (PMR) was applied to represent gene methylation level.
Results: Our data indicated that PRMT6 promoter methylation levels were significantly lower in CRC tissues than those in paired nontumor tissues (median PMR:
36.93% vs 63.12%, P = 1E-6) and normal intestinal tissues (median PMR: 36.93% vs 506.55%, P = 8E-12). We further examined the potential role of PRMT6 hypomethylation by the receiver operating characteristic (ROC) curve. Our results showed that the area under the curve (AUC) was 0.644 (95% CI = 0.596-0.733) between CRC tissues and paired nontumor tissues, 0.958 (95% CI = 0.919-0.998) between CRC tissues and normal intestinal tissues, and 0.899 (95% CI = 0.825-0.972) between paired nontumor tissues and normal intestinal tissues.
Conclusion:
Our study firstly indicated that the hypomethylation of PRMT6 promoter could be a novel diagnostic biomarker for CRC.
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colorectal cancer, DNA methylation, protein arginine N-methyltransferase 6, quantitative methylation-specific polymerase chain reaction prostate cancer, 14 breast cancer, 15, 16 and lung cancer. 17 However, no article was reported on whether PRMT6 hypomethylation was associated with CRC.
Here, we assessed the association between PRMT6 promoter methylation and CRC. The goal of our study was to determine whether PRMT6 hypomethylation could be used as a diagnostic biomarker for CRC.
| MATERIAL S AND ME THODS

| Tissue samples
A total 121 CRC patients (mean age, 61.62 ± 11.55 years) were re- Normal intestinal tissues were collected from healthy participants.
Tumor tissues and their paired nontumor tissues were taken in the same block and layer. 18 All the clinical information was extracted from the medical records ( 
| DNA extraction, bisulfite conversion, and qMSP
The details of DNA extraction from tissue samples and bisulfite conversion were as previously described. 6 The qMSP was applied to measure the methylation level, and the details of qMSP were as shown in our previous publications. 7, 19 The detail of PCR was conducted as before 6 and the qMSP primer sequences were shown in 
| GEO and TCGA datasets
To evaluate the association between PRMT6 methylation and PRMT6 expression, the data of 372 samples in TCGA colorectal adenocarcinoma cohort was downloaded from cBioPortal (http://www.
cbioportal.org/). Meanwhile, data with PRMT6 expression changes in several cancer cell lines before and after 5′-AZA-deoxycytidine (5-AZA) treatment was retrieved from GEO DataSets (GSE38823, https://www.ncbi.nlm.nih.gov/pubmed).
| Statistical analysis
Nonparametric rank test was used to assess the methylation differences between two groups. Spearman correlation test was used to assess the correlation between PRMT6 methylation and clinical characteristics. ROC curve analysis was used to assess the diagnostic value of PRMT6 promoter methylation for CRC. A two-sided P < .05 was defined to be statistically significant.
| RE SULTS
The target fragment in promoter was used to represent the methylation level of PRMT6 gene (GRCh37/hg19 assembly, chr1:107599926-107599989, Figure 1A ). In addition, Sanger sequencing manifested that the amplified fragment matched the target sequence and the bisulfite conversion was complete ( Figure 1B ). Capillary electrophoresis showed that the length of PRMT6 target fragment was 64 bp as expected ( Figure 1C ).
To evaluate the value of PRMT6 methylation in the diagnosis of CRC, we recruited tumor tissues and paired nontumor tissues of 121 CRC patients and normal intestinal tissues of 22 healthy participations. Our study showed that the methylation levels of PRMT6 promoter were significantly lower in CRC tissues than those in the paired nontumor tissues (P = 1E-6, Figure 2 ), and than those in the normal intestinal tissues (P = 8E-12, Figure 2 ). In addition, we also observed significantly lower PRMT6 methylation levels in the paired nontumor tissues compared to those in normal intestinal tissues (P = 3E-9, Figure 2 ).
Further ROC curve analysis showed that the AUC was 0.644 samples. Then, we used ROC best value (73.0%) as cutoff value to divide the PRMT6 methylation levels into either hypermethylation or hypomethylation, and we found that the PPV of PRMT6 hypomethylation in tumor was 64.1%, which was higher than the PPV of CEA (33.3%).
Subsequently, we examined the correlation between PRMT6 methylation and the clinicopathological features of CRC patients.
Our results showed that PRMT6 methylation in tumor was not significantly associated with gender, age, clinical stage, differentiation, tumor size or lymph node metastasis of the patients (all P > .05, Table 1 ). There was a significant correlation between PRMT6 hypomethylation and differentiation in paired nontumor tissues (P = .032, Table 1 ), and there was no significant correlation of PRMT6 hypomethylation with other clinical features (all P > .05, Table 2 ).
In addition, an inverse correlation between PRMT6 methylation and PRMT6 expression was observed according to our analysis of data from 372 TCGA colorectal adenocarcinoma samples (r = −.378, P = 4E-14, Figure 4A ). In addition, GEO data analysis showed that PRMT6 expression was significantly increased when cell lines (SAS and HCS3) were treated with demethylation agent (5-AZA, fold changes (FC) = 1.30 and 1.16, Figure 4B ).
F I G U R E 1
The target sequence of PRMT6 methylation assay. A, The genomic position and functional annotation of amplified fragment were based on UCSC genome browser GRCh37 assembly. The qMSP primers are underlined, and one CpG sites are in gray. F denotes forward primer; R denotes reverse primer. B, The picture on the left is the sequencing result of PRMT6 qMSP product. The top row of the sequence is the original DNA sequence; the second row of the sequence is the converted sequence. C, The results of capillary electrophoresis. The first column is the marker band; the second column is the blank control; the third column is 64-bp qMSP product as expected
| D ISCUSS I ON
In this study, we analyzed PRMT6 methylation levels of tumor tissues with those in the paired nontumor tissues and normal intestinal tissues. Moreover, we evaluated the correlations between PRMT6 methylation and a series of clinical features. Our results showed that PRMT6 methylation levels were significantly lower in tumor tissues than those in nontumor and normal intestinal tissues. These findings led us to speculate that PRMT6 hypomethylation might be used as a diagnostic biomarker of CRC.
PRMTs can methylate the arginine residues of proteins, 13 including p16 and p21 which are tumor suppressor proteins. 16, 20, 21 Methylation of p16 usually resulted in decreased protein function and promoted tumorigenesis. 22 The p21 gene encodes a cyclindependent kinase inhibitory protein with tumor suppressor activity. 23 The p21 plays an important role in the development and progression of cancer, 24 and hypermethylation of p21 leads to downregulation of p21 gene expression. In the present study, we found PRMT6 hypomethylation was significantly associated with CRC. Meanwhile, TCGA and GEO data analyses showed that PRMT6 methylation was inversely correlated with mRNA expression. We hypothesized that PRMT6 hypomethylation might increase the expression of PRMT6 protein and thus promotes cell proliferation by downregulating tumor suppressor genes. 27 As a noninvasive method widely used in the detection of CRC, fecal occult blood test (FOBT) comprises guaiac (gFOBT) and immunochemical (iFOBT). However, the gFOBT test was easy to be effected by other factors, resulting in false-positive results. The detection rate of iFOBT decreased rapidly once the time from collection to laboratory inspection was deferred for over 5 days. [28] [29] [30] As for colonoscopy, despite its high sensitivity and specificity, there were still some shortcomings, such as complications (intestinal gastrointestinal bleeding, intestinal perforation,) and low compliance. 31 Carcinoembryonic antigen (CEA)
in serum is one of the biomarkers widely used in the diagnosis of cancer; 32 however, it is still defective because increased CEA levels were not only found in cancer patients but also in smokers, which reduced its specificity in cancer diagnosis. 33, 34 Meanwhile, CEA lacks ideal sensitivity in the early diagnosis of CRC. 35, 36 A review based on 9834 CEA test results indicated that the sensitivity of CEA ranged from 50% to 80%. 37 In addition, the sensitivity of serum CEA in detecting the risk of CRC recurrence was only 64%. 38 Here, our study found that PRMT6 hypomethylation had a specificity of 78.5% and a sensitivity of 95.5% for the detection of CRC, and we also found the PPV of PRMT6 hypomethylation was higher than that of serum CEA. However, future investigation is needed to access the combined diagnosis of PRMT6 methylation and CEA levels for CRC.
F I G U R E 2
Comparisons of percentage of methylated reference (PMR) of PRMT6 between tumor tissues, paired nontumor tissues, and normal intestinal tissues. PMR denotes the percentage of methylated reference, and data are presented as median (interquartile range). P value is calculated by a nonparametric test F I G U R E 3 ROC curves of PRMT6 hypomethylation as a diagnostic biomarker for colorectal cancer (CRC). ROC curve for the diagnostic value of PRMT6 hypomethylation between CRC tumor tissues and para-tumor tissues A, between CRC tumor tissues and normal intestinal tissues B, between para-tumor tissues, and normal intestinal tissues C, ROC: receiver operating characteristic. AUC: area under the curve
The benign colorectal disease can gradually progress to advanced adenoma and invasive adenocarcinoma. [39] [40] [41] Abnormal gene methylation was found in hyperplastic polyps with cancerous potential. 42 Previous studies identified that there was aberrant methylation of multiple genes between CRC tissues and colorectal benign polyp tissues and between colorectal benign polyp tissues and healthy intestinal tissues. [43] [44] [45] [46] [47] [48] In the present study, we did not perform the similar comparison due to a lack of expression. However, our TCGA data analysis showed an inverse correlation between PRMT6 methylation and PRMT6 expression.
In summary, we found a significant association of PRMT6 hypomethylation with CRC. Our results suggested that PRMT6 hypomethylation might be used as a diagnostic biomarker for CRC, although further validation with large samples is needed in the future.
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